Immunomodulatory, antibacterial and antineoplastic potential of Trichilia catigua A. Juss. (Meliaceae) bark extracts and isolated compound cinchonain Ib.

Immunomodulatory, antibacterial and antineoplastic activity of crude extract (CE), aqueous (AqF), and ethyl-acetate fractions (EAF) from the barks of Trichilia catigua, and cinchonain Ib EAF-isolated were investigated. CE, AqF, and EAF treatment induced significantly decreased levels of IL-6, IL-17A and IL-22 cytokines. IFN-y and IL-10 showed significant decreases after CE treatment. Cinchonain Ib significatively reduced IL-17A, IFN-y, TNF-α, IL-2 and IL-6 levels. All tested extracts and fractions showed antibacterial activity against Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus (MRSA). Cinchonain Ib exhibited MIC (31.25 µg/mL) and MBC (250 µg/mL) against S. aureus, MRSA and S. epidermidis clinical isolate. CE and EAF treatments showed cytotoxicity in HL-60 and TOLEDO cells. EAF treatment was cytotoxic in MCF-7 cells. Cinchonain Ib presented cytotoxicity to K562 (IC50=46.21±3.9), HL-60 (IC50=51.83±3.17) and MOLT-4 (IC50=57.52±4.57) cells. These results evidenced the availability of uses of T. catigua and cinchonain Ib as immunomodulatory, antineoplastic, bacteriostatic and bactericidal agent.